Lead in – or NOT? Graham R Foster Professor of Hepatology Queen Marys University of London.

Slides:

Advertisements

Similar presentations

Douglas T. Dieterich, Juergen K. Rockstroh, Kenneth E. Sherman, Nathalie Adda, Lisa Mahnke, Varun Garg, Shahin Gharakhanian, Scott McCallister, Vincente.

Advertisements

Hepatitis C The next generation of Treatment for Hepatitis C.

Traitement de l’Hépatite C Sans Interféron Patrick Marcellin.

Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.

What’s new in HCV genotype 2? Alessandra Mangia S.Giovanni Rotondo,ITALY PARIS HEPATITIS CONFERENCE January 2012.

Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.

Protease and Polymerase Inhibitors for the Treatment of Hepatitis C

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

HCV resistance Understanding the mechanism and Prevention

WHAT FUTURE FOR RIBAVIRIN? Mitchell L Shiffman, MD Chief, Hepatology Section Medical Director, Liver Transplant Program Virginia Commonwealth University.

Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.

Management of non naïve patients with hepatitis C Relapsers Alessandra Mangia Liver Unit & Division of Gastroenterology “CSS” San Giovanni Rotondo, Italy.

Direct Acting Antivirals: What are they

How to manage non responders Lawrence Serfaty Service d’Hépatologie, UMR S 893 Hôpital Saint-Antoine, UPMC, Paris Clinical case 1.

The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.

Treatment of Hepatitis C in patients with thalassaemia

Liver Institute of Virginia Education, Research and Treatment for Patients with Liver Disease IVer Bon Secours Health System WHY CHOOSE TELAPREVIR Mitchell.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

The Future: Is Ribavirin Still Useful? David Nelson, MD Professor of Medicine, Microbiology, and Molecular Genetics Associate Dean, Clinical Research and.

Practical management of PI therapy in Hepatitis C Paris Februari 2012 Ola Weiland Karolinska Institutet Stockholm, Sweden.

Hepatitis C Genotype 3 Paris 2012 Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.

Controversies: Lead in or no lead in ? PRO Controversies: Lead in or no lead in ? PRO Lawrence Serfaty Hôpital Saint-Antoine Paris 5th Paris Hepatitis.

Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Boceprevir (Victrelis) Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated: March.

HCV EASL CPG 2011: what is (still) new? Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Management of Patients Co- infected with HCV and HIV: A Close Look at the Role for DAAs Susanna Naggie, MD Assistant Professor of Medicine Division of.

Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin Paul Y Kwo, MD Professor of Medicine Medical Director,

Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Terapia dell’Epatite cronica HCV correlata: Peg-IFN/ribavirina e che altro? L’infettivologia del terzo millennio: non solo AIDS Paestum maggio 2006.

Alessio Aghemo First Division of Gastroenterology Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Università degli Studi di Milano 5 th Paris.

Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.

Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.

Hepatitis web study Hepatitis web study Simeprevir with Peginterferon and Ribavirin in GT-4 RESTORE Phase 3 Treatment Naïve and Treatment Experienced Moreno.

SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.

How to optimize treatment of G1 patients? Prof. G. K. K. Lau 2012.

NS5A and polymerase inhibitors Mark Sulkowski, MD Professor of Medicine Johns Hopkins University Baltimore Maryland

Predictors of treatment response, baseline and on-treatment A case study of telaprevir therapy Alex Thompson.

How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.

Future treatment of patients with HCV cirrhosis Marc Bourlière Dept of Hepato-gastroenterology 5 th Paris Hepatitis Conference Saint Joseph Hospital, Marseille.

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.

How to avoid a resistance issue with the first generation protease inhibitors ? O. Lada PHD Service d’Hépatologie et INSERM CRB3, AP-HP Hopital Beaujon,

Hepatitis C When, how and which patients should be treated Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.

Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.

Hepatitis C Nonresponders

#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.

AASLD 2010 HCV Feedback October 29 - November 2, 2010 Boston, Massachusetts Dr Allister J Grant Consultant Hepatologist Leicester Liver Unit.

Triple Therapy Today Phase III Results in G1 Relapsers and Non Responders – Telaprevir 5 th Paris Hepatitis Conference Paris, 30. January 2012 Stefan Zeuzem.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.

Hepatitis web study Hepatitis web study Simeprevir versus Telaprevir with PR in GT1 ATTAIN Trial Phase 3 Treatment Experienced Reddy KR, et al. Lancet.

36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago First treatment with PEG-IFN/RBV in 2002 –only qualitative PCR available : positive at.

‘Easy to treat’? Graham R Foster Professor of Hepatology Queen Marys University of London.

Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Milan, Italy ELPA Symposium: COMPASSIONATE USE IN HEPATITIS C What patients populations.

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

CONCERTO-2 Study: SMV + PEG-IFNa-2a + RBV for genotype 1

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

Resistance to Direct Acting Antiviral Therapy

Simeprevir in HIV Coinfection, GT-1 C212 Trial

HCV Protease Inhibitors in Clinical Practice

Volume 59, Issue 4, Pages (October 2013)

HCV Protease Inhibitors in Clinical Practice

What Does the Future Hold and What Will It Mean for Patients?

Telaprevir in Treatment Experienced GT-1 PROVE3

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

Presentation transcript:

Lead in – or NOT? Graham R Foster Professor of Hepatology Queen Marys University of London

Lead in or NOT? Conflicts of interest I have received funding from Janssen, Merck, Roche, Gilead, BMS, BI, Abbott. The views expressed here are for the purposes of argument (and may, or may not) reflect my own views.

Why lead in is of no value The evidence The convenience of starting therapy The dangers of lead-in

Why lead in is of no value The evidence The convenience of starting therapy The dangers of lead-in

REALIZE (Telaprevir): Study Design (N=662) Weeks 72 T12/PR48 Peg-IFN + RBV TVR + Peg-IFN + RBV Pbo + Peg-IFN + RBV N=266 Follow-up SVR assessment TVR + Peg-IFN + RBV Peg-IFN + RBV LI T12/ PR48 N=264 Follow-up Pbo + Peg-IFN + RBV PR48 (control) Pbo + Peg-IFN + RBVPeg-IFN + RBV N=132 Follow-up Zeuzem NEJM 2011

REALIZE (Telaprevir): Study Design (N=662) Weeks 72 T12/PR48 Peg-IFN + RBV TVR + Peg-IFN + RBV Pbo + Peg-IFN + RBV N=266 Follow-up SVR assessment TVR + Peg-IFN + RBV Peg-IFN + RBV LI T12/ PR48 N=264 Follow-up Pbo + Peg-IFN + RBV PR48 (control) Pbo + Peg-IFN + RBVPeg-IFN + RBV N=132 Follow-up Zeuzem NEJM 2011

Impact of lead in (treatment experienced) SVR (%) PR48 16/68 T12/PR48 121/145 LI T12/ PR48 124/141 n/N= PR48 6/64 T12/PR48 50/121 LI T12/ PR48 51/123 Prior relapsersPrior non-responders (prior partial responders + null responders) * * * * Zeuzem S, et al. J Hepatol 2011;54(Suppl. 1):S3 *p<0.001 vs PR48

Why lead in is of no value The only proper evaluation of lead-in shows no benefit

Controlled trial of 3 day lead in (SILEN-C1 (BI )) n=71 n=69 n=143 n=146 PRPlacebo + PR PR 120mg QD LI BI PR a PR 240mg QD BI PR a PR 240mg QD LI BI PR D1D4Week 24Week 48 Sulkowski MS, et al. Hepatology 2011;54(Suppl. S1): Abstract 226

Controlled trial of 3 day lead in (SILEN-C1 (BI )) n=71 n=69 n=143 n=146 PRPlacebo + PR PR 120mg QD LI BI PR a PR 240mg QD BI PR a PR 240mg QD LI BI PR D1D4Week 24Week 48 Sulkowski MS, et al. Hepatology 2011;54(Suppl. S1): Abstract 226

Controlled trial of 3 day lead in (SILEN-C1 (BI )) 40/7149/69103/142118/14211/7155/69111/142124/ Proportion of patients (%) eRVRSVR PR120mg QD LI240mg QD LI240mg QD Sulkowski MS, et al. Hepatology 2011;54(Suppl. S1): Abstract 226

Why lead in is of no value The only proper evaluation of lead-in shows no benefit There is a suggestion that lead in may be harmful!

Why lead in is of no value The evidence The convenience of starting therapy The dangers of lead-in

Lead in is unpopular with patients Patients have waited 10 years for these drugs, now you want them to start with the old stuff? Patients don’t want to come back in four weeks and start again

Lead in is unpopular with patients

Patients want to start with the new therapy Patients want the best treatment straight away

Why lead in is of no value The evidence The convenience of starting therapy The dangers of lead-in

The Dangers of Lead In Lead-in may persuade you NOT to start the protease inhibitor (If your patient is HCV RNA negative at 4 weeks, would you start a PI?)

How do patients fail therapy? Detection limit Relapse Null response Breakthrough Adapted from Shiffman M. Curr Gastroenterol Rep 2006;8:46–52; Neumann A, et al. Science 1998;282:103–7; De Bruijne J, et al. Neth J Med 2008;66:311–22 Partial response Treatment Non-response HCV RNA level Weeks

How do patients fail therapy? Detection limit Relapse Null response Breakthrough Adapted from Shiffman M. Curr Gastroenterol Rep 2006;8:46–52; Neumann A, et al. Science 1998;282:103–7; De Bruijne J, et al. Neth J Med 2008;66:311–22 Partial response Treatment Non-response HCV RNA level Weeks

Relapse – the hidden rocks You only know who is going to relapse when you stop therapy All Peg+ Riba relapsers will need re-treating

What happens if 95% of RVR patients respond? What happens to those who fail? Pre-treatment prediction accuracy 95% Another 12 months + DAA

What happens to those who fail? Pre-treatment prediction accuracy 75% Another 12 months + DAA Is this cost effective? What happens if 75% of RVR patients respond?

Lead - in Lead in is of unproven value Lead in is unpopular with patients Lead in leads you to make bad treatment choices

Lead in Lead – in is NOT being used in any of the current DAA trials Is lead in really such a good idea?